The limited availability of human embryonic tissue for dopamine cell transplants in Parkinson's patients has led to an increased interest in using xenogeneic donor tissue. Unfortunately, without aggressive immunosuppression, such brain xenografts are rejected by the host immune system. Chronic brain xenograft rejection is largely mediated by helper T cells, which require presentation of xenoantigens by major histocompatability complex (MHC) class II for their activation. We examined survival and function of xenografts of E13 mouse mesencephalon deficient in either MHC class I, class II, or both after transplantation into adult hemiparkinsonian rats without immunosuppression. Recipients received grafts from C57BL/6 mice that were either: 1) wild-type (wt), 2) MHC class I knockout (KO), 3) MHC class II KO, 4) MHC class I and II double KO, or 5) saline sham transplants. At 6 weeks after transplantation, recipients of MHC class I KO, class II KO, and double KO xenografts significantly reduced methamphetamine-induced circling rate while rats with wt xenografts and sham-operated rats showed no improvement. MHC class II KO grafts had the greatest number of surviving dopamine neurons. All transplants, including saline sham controls, contained infiltrating host MHC class II-positive cells. Saline sham grafts and MHC class II KO xenografts contained significantly fewer infiltrating host MHC class II-positive cells than did wt grafts. Our results show that MHC class II-deficient xenografts survive transplantation for at least 6 weeks in the absence of immunosuppression, reduce rotational asymmetry, and provoke lesser immune reaction than wt grafts.
INTRODUCTION
establish a stable source of dopaminergic tissue, which would elicit fewer ethical concerns and be suitable for human transplantation. Xenografts from pigs and cows Transplantation of dopamine cells from human fetal mesencephalon into the striatum of patients with Parkin-have been transplanted into rats (29, 30, 37, 60) and porcine neural tissue has been grafted into humans (15, 20) . son's disease has been investigated in an effort to replace degenerating dopamine terminals originating in the sub-Nonetheless, xenografts constitute an enormous challenge to the immune system of the transplant recipient. stantia nigra (36) . Animal models of Parkinson's disease established the efficacy of such transplants and also Embryonic neural grafts, which are tolerated by a host of the same species (allogeneic), are rapidly rejected by demonstrated that within-species allografts of embryonic brain tissue are rarely rejected (5). In human patients a xenogeneic host of a different species (6, 21, 22, 24, 25) . Immunosuppression with cyclosporin A can moderate the with advanced Parkinson's disease, transplants of human fetal mesencephalic tissue are effective in moderating host immune response (7, 33, 44, 45) but is expensive and can produce hypertension, renal and CNS toxicity, and symptoms and improving the quality of life (26) (27) (28) 35, 38, 39) .
increased susceptibility to infection and malignancies. The brain is thought to be an immunologically privi-Neural transplantation in Parkinson's disease patients is limited by tissue availability and the political contro-leged site protected from lymphocyte infiltration by the blood-brain barrier. This barrier, however, is breached versy surrounding abortion. It is therefore desirable to 6 VENG ET AL. upon transplantation when brain tissue and blood vessels responses to the neural xenografts can be partly alleviated by administering antibodies to CD4, which result are disrupted, allowing immune cells access to the brain (53). In the absence of disease or disruption, levels of in intrathymic depletion of CD4 + helper T cells (59) . Others seeking to reduce the immunogenicity of xe-major histocompatability complex (MHC) expression in the brain are low but the trauma of transplantation in-nografts have used cell preparations of bovine chromaffin cells that have been depleted of MHC-expressing duces MHC expression on host glial cells and enables cell-mediated immunity (14, 52) . Host T-cell activation nonchromaffin passenger cells (14, 50) . The survival of such xenografts is markedly improved by removing the has been shown to be critical for transplant rejection (48). Activation of helper T cells requires presentation MHC-expressing cells from the preparation. In vitro Tcell proliferation in response to the isolated chromaffin of xenogeneic peptide fragments by the host and/or donor MHC class II molecules present on the surface of cells is negligible when compared with T-cell responses to the MHC-expressing nonchromaffin cells (13) . The antigen presenting cells (APCs) (2, 31) .
Host T cells can detect donor antigens by direct or indi-use of MHC-deficient donors in allotransplantation of peripheral organs demonstrated that the host immune re-rect recognition (31) . In direct recognition, donor MHCs on donor APCs interact with host helper T cells (CD4 + sponses to MHC-deficient grafts was greatly reduced, although the strength of this response was dependent on T cells), which recognize the donor MHC complex as foreign and become activated. With indirect recognition, the type of tissue transplanted (9, 12) . MHC-deficient murine pancreatic islet allografts have been reported to sur-processed donor MHC peptides are presented to host T cells by host MHCs on host APCs. In either scenario, vive indefinitely without immunosuppression (40) . Deficiency in either MHC class I or II in the mouse ventral xenogeneic MHC molecules or processed MHC peptides are potent activators of the host T-cell-mediated immune mesencephalic donor tissue permitted graft survival for at least 6 weeks in striata of naive rats (18). reaction and initiate graft rejection. Although direct recognition is thought to be the primary mechanism for xenoge-We hypothesized that the absence of MHC molecules on donor neural tissue might alleviate host immune reac-neic graft recognition, the role of indirect recognition in xenograft rejection continues to gain more recognition tions and prevent, or delay, neural xenograft rejection in an animal model of neurodegeneration. In the present (3, 31) .
Once activated, helper T cells secrete interleukin-2 study, we have evaluated the ability of tissue from MHCdeficient donor mice (32) to improve the survival of neu-(IL-2), which causes proliferation of helper T cells and initiates activation and proliferation of cytotoxic T cells ral xenografts and promote behavioral recovery in a rat model of Parkinson's disease. The present results show (CD8 + T cells) and antibody-producing B cells (2, 52) . Cytotoxic T-cell precursors become activated by simul-that MHC-deficient neural xenografts survive without immunosuppression and improve behavioral recovery in taneous exposure to IL-2 and xenoantigen complexed with MHC class I on APCs. The MHC class I complex hemiparkinsonian rats and suggest that lack of MHC class II expression on donor tissue reduces infiltration interacts with both the cytotoxic T-cell CD8 molecule and the T-cell receptor. Resulting from this cascade, activated of APCs into xenografts. cytotoxic T cells and other effector cells are recruited into MATERIALS AND METHODS the xenograft and carry out the cell-mediated rejection 6-Hydroxydopamine (6-OHDA) Lesion process. CD4-and CD8-positive T cells have been shown to infiltrate brain xenografts as early as 3 days after trans-Adult male Sprague-Dawley rats (250-300 g) were used in this study. Rats were anesthetized with Equith-plantation (43) and have been observed in brain several months following neurotransplantation in animals and esin (4 mg/kg) and unilaterally lesioned by injecting 6hydroxydopamine (6-OHDA) (20 µg total) in 4 µl into humans (15, 43, 60) . Brain xenograft rejection is further exacerbated by the complement-mediated (humoral) im-two sites of the left medial forebrain bundle at the following stereotaxic coordinates: AP −2.1 mm posterior mune response (4) .
In an effort to improve xenograft survival, recent to bregma, LAT 2.0 mm from midline, and AP −4.3 mm posterior to bregma, LAT 1.5 mm from midline at a studies have focused on modifying the host immune response to xenogeneic neural transplants. Manipulating depth of 7.8 mm below dura. The extent of each lesion was evaluated by measuring the number of ipsilateral T-cell-mediated host immunity has been shown to protect xenografts from immune rejection. One study using turns in response to an IP injection of 5 mg/kg methamphetamine. Rats were place in flat-bottomed Plexiglas a short-term combination treatment with antibodies against T-cell receptor αβ and the T-cell surface mole-cylinders and the circling rate was recorded during the last 90 min of a 120-min session. Animals circling above cule CD2 demonstrated induction of donor-specific tolerance and long-term survival of the neural mouse-to-three rotations per minute (rpm) were divided into five groups (see Table 1 ) with a mean rotational rate of 9.2 rat xenograft (43) . Others have shown that host immune rpm, such that all groups were behaviorally equivalent Freez) and monoclonal anti-rat MHC class II (OX-6; Serotec). ABC vectastain kit (Vector) was used for de-prior to transplantation. Only rats that rotated at 3 rpm or greater were included in this study. We have pre-tection of the primary antibodies and diaminobenzidine was used for visualization. Hematoxylin-eosin staining viously demonstrated that in our drug-induced circling test performed in flat-bottomed Plexiglas cylinders cir-was used to determine the extent of lymphocyte infiltration. TH + cells were counted in every third section though cling above 2 rpm correlates with >95% dopamine depletion (46). By contrast, Ungerstedt and Arbuthnott demon-the graft site and the total number of surviving TH + cells in each graft was determined using Abercrombie's cor-strated that, when methamphetamine-induced circling test is performed in hemispherical bowls instead of cylin-rection (1) . Rat MHC class II + cells were counted in a single section from the middle of each transplant. ders, higher circling rates (4-6 rpm) predict >95% dopamine depletion (58) .
Statistical Analysis Neurotransplantation
All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) and In-Transplant groups and sources for the transgenic mice stat (GraphPad) software. A repeated measures analysis are shown in Table 1 . Transplantation was performed 2 of variance (ANOVA) was performed on data from the weeks following the completion of behavioral testing. Rats methamphetamine-induced rotation tests to evaluate the were anesthetized with Equithesin and transplants were extent of behavioral recovery in each animal. Planned stereotaxically placed into the striatum on the lesioned comparisons of pre-versus posttransplant performance (left) side at AP 0.0 mm from bregma, LAT 3.0 mm were carried out using two-tailed paired t-tests for each from midline, and VD 7.5-3.5 mm below dura. Ventral group. Group differences in number of surviving transmesencephalic tissue was dissected out from E13 mouse planted dopamine neurons and group differences in numdonors in sterile Hank's balanced salt solution. For ber of rat MHC class II-positive cells in the striatum were transplantation, one mouse ventral mesencephalon was analyzed using one-way ANOVA. For each animal, the shaped into a tissue strand (200 µm in diameter) by number of dopamine neurons in the transplant was comextruding tissue through a tapered glass cannula made puted using Abercrombie's correction. The relationship by heating a commercially available glass rod (Kimble of neuron number to behavioral performance was inves-Kontes, Cat. No. 663500-0444). All animals received tigated using a nonparametric Spearman correlation. transplants of one ventral mesencephalon in 4 µl of sterile saline, injected into a 4-mm-long transplant tract over RESULTS 4 min using a Hamilton syringe connected to a motor-Behavioral Recovery ized pump. No immunosuppression was used.
Six weeks after transplantation, all groups of rats were Histological and Behavioral Evaluation evaluated for behavioral recovery by the methamphet-Six weeks after transplantation, rats were reevaluated amine-induced circling test ( Fig. 1 ). At 6 weeks after for their methamphetamine-induced circling, sacrificed, transplantation, rats receiving grafts of MHC class I and transcardially perfused with ice-cold phosphateknockout (KO), MHC class II KO, and double KO tissue buffered saline followed by 4% paraformaldehyde. Brains significantly reduced their drug-induced circling rate were removed, cryopreserved in 30% sucrose, and the compared with pretransplant values. Behavioral outcome graft-containing areas were sectioned in a coronal plane of the transplants was analyzed by comparing pretransat 40 µm on a cryostat. Sections were processed for typlant circling rate against posttransplant circling rate for rosine hydroxylase (TH) and rat MHC class II immunoall groups, F(1, 43) = 27.75, p < 0.001. The greatest decytochemistry following blocking and inactivation of gree of behavioral recovery was seen in animals transendogenous peroxidases with hydrogen peroxide. Priplanted with MHC class II-deficient tissue. At 6 weeks, mary antibodies used were polyclonal anti-rat TH (Pelthese animals rotated at 37.5 ± 15.7% of their pretransplant rpm (p < 0.01). Significant reduction in drug-induced circling was also seen in animals receiving MHC class grafted animals rotated at 81.4 ± 11.5% of their pretransplant rpm.
Graft Survival
Transplants were evaluated for graft survival by TH immunohistochemistry at 6 weeks after transplantation. To quantitate dopamine neuron survival the number of TH + neuronal cell bodies was counted in every third section through the graft site and the total number of dopamine neurons per graft was estimated using Abercrombie's correction (1) . Figure 2 shows the mean number of TH + cells/graft in each group. The greatest number of TH + neurons (181 ± 84) was found in the MHC class IIdeficient transplants (Fig. 2) . In transplants of MHC in the group grafted with MHC class II-deficient donor I-deficient tissue attracted 238 ± 55 infiltrating host MHC class II + cells. By contrast, grafts of MHC class II-deficient tissue contained significantly fewer (187 ± 41) host MHC class II + cells (p < 0.05) when compared with the wild-type grafts, F(4, 37) = 3.93, p < 0.01. The double KO grafts attracted a similar number of host MHC class II + cells (176 ± 48) as the MHC class II-deficient grafts. However, because the variability in the double KO group was slightly greater, this result did not reach statistical significance. Saline infusion alone attracted 49 ± 14 infiltrating rat MHC class II + cells to the injection site, and this number was significantly lower than that induced by the wild-type grafts (p < 0.01). This finding demonstrates that mere mechanical disruption of brain tissue as observed here in the sham animals can induce expression of host MHC class II molecules. Photomicrographs showing the intensity of host MHC class II + infiltration are shown in Figure 6 . Our findings suggest that deficiency in MHC class II molecules on donor cells can mask these cells from the host immune recognition and dopamine neurons at 6 weeks postgrafting was sufficient to abolish circling in animals injected with methamphetamine, regardless of the MHC status of the donor tissue. These results suggest that neural xenografts can fully compensate for the loss of nigrostriatal dopamine even in the absence of immunosuppression.
Host MHC Class II Expression
The immunogenicity of MHC-deficient neural xenografts has not been previously evaluated in hemiparkinsonian rats. Many authors report that the brain has some degree of immune privilege and that MHC class II expression in the brain is low, but can be upregulated by an ischemic insult (23) or the deposition of immunogenic tissues (21,52). Therefore, we were interested in evaluating the extent to which MHC-deficient xenografts could induce rat MHC class II expression in the wild-type grafts (Fig. 5) . Similarly, grafts of MHC class 
DISCUSSION
problems caused by the limited and variable supply of human fetal tissue. Ethical concerns further impede progress in the field of cell replacement therapy. Be-We have examined if genetic deficiency in donor MHCs can rescue neural xenografts in a rat model of tween-species xenografting offers a potential solution to these problems. First of all, xenogeneic donor tissue can Parkinson's disease. Our results demonstrate that mouseto-rat neural xenografts deficient in MHC class I, MHC be cloned to provide genetic homogeneity among donors, which would greatly facilitate comparisons be-class II, or both, survive for at least 6 weeks after transplantation and are effective in improving behavioral re-tween different transplantation protocols and transplant recipients. Second, a properly managed xenogeneic tis-covery in hemiparkinsonian rats. Neural xenografts from MHC class II-deficient donors showed the best dopa-sue source could eliminate the problem of donor scarcity. Therefore, the interest in studies of xenograft func-mine cell survival and the fewest infiltrating rat host MHC class II + APCs, suggesting that donor MHC class tion and survival has increased. Porcine, murine, bovine, and human ventral mesencephalic tissues have all been II peptides represent an important determinant for host T-cell activation and chronic xenograft rejection in the transplanted in a rat model of Parkinson's disease (6, 29, 30, 34, 37, 60) . Although such xenografts survive trans-brain. Our findings are supported by a study by Duan et al., who showed that transplants of MHC class I-and plantation, the transplant recipients must be permanently immunosuppressed (7) . In all cases, the xenografts were class II-deficient mouse tissue into striata of naive rats survive longer than wild-type grafts (18). Survival of rejected after the immunosuppression was discontinued (34) . Xenografts implanted without protection of immu-MHC class II-deficient mouse dopamine neurons in our study is similar to that observed by Duan et al. (18). By nosuppressive drugs, such as cyclosporin A, are generally rejected within 3 weeks of transplantation (19). contrast, our study showed lesser survival of MHC class I-deficient grafts than that observed by Duan et al. (18) .
An ongoing clinical trial is testing the efficacy of using fetal porcine mesencephalic tissue in transplants into These differences might be in part caused by the differences in the experimental models (i.e., use of naive the brains of Parkinson's disease patients (15) . One postmortem case report revealed that, although several hun-transplant recipients) (18) and parkinsonian rats (our study). Despite survival of MHC-deficient grafts in the dred dopamine neurons survived in the xenograft, most of the transplanted cells were rejected by 8 months post-naive rats (18), the number of TH + cells declined in these transplants when compared with cell survival in transplantation despite aggressive immunosuppression. The extent of interest in neural xenografts is exemplified the wild-type grafts placed in immunosuppressed rats, which remained constant over the 6-week period (18).
by the commitment of biotechnology companies to actively pursue studies of cellular xenografts in humans (15, Alternative methods for xenograft protection such as masking MHCs using an antibody have also shown con -20) . Current immunosuppressive regimens are expensive, insufficient, and predispose the recipient to oppor-siderable promise. Preincubation of xenogeneic human islet cells with monoclonal F(ab′) 2 antibody fragments to tunistic infections and malignancies such as lymphoma. These immunosuppressants act downstream of the initial human lymphocyte antigen, before transplantation into mouse recipients, permits xenograft survival for at least events that trigger the immune response. Novel immunosuppressant strategies, such as removal or masking of 200 days (19) .
In our study, the degree of behavioral recovery corre-the MHC molecules that inhibit the earliest events in the immune cascade, may prove to be more effective than lated with the number of surviving dopamine neurons, demonstrating that neural xenografts of MHC-deficient currently available pharmacological immunosuppression. Mouse neural xenografts can alleviate hemiparkin-ventral mesencephalon can innervate host striatum and function to improve parkinsonian symptoms in rats. Oth-sonian symptoms in rats immunosuppressed with cyclosporin A (7, 22) or in which host T-cell-mediated immune ers have shown that human-to-rat neural xenografts of ventral mesencephalon specifically innervate host stri-responses are blunted with antibody therapy (43, 57) . Using an alternative approach, we have demonstrated that atum, form synapses on host striatal neurons, and release dopamine (8, 11, (54) (55) (56) (57) . Our results indicate that re-MHC-deficient mouse-to-rat neural xenografts can survive in the absence of any immunosuppressive therapy. moval of MHC class II molecules by genetic modification of donor tissue does not negatively impact survival
These results suggest that host immune recognition of donor tissue is, at least partly, dependent on donor MHC and function of neural xenografts. On the contrary, such MHC-deficient tissue appears to be less immunogenic expression and that donor MHC class II expression is a potent inducer of the host immune reaction and an im-and may prolong xenograft survival and augment its function.
portant determinant of cell-mediated immune rejection.
In the present study, rats grafted with wild-type mouse Although many studies have addressed the issue of allograft survival, only a few have examined the major ventral mesencephalon failed to show any behavioral improvement and only three out of nine grafts had any anti-MHC class II antibodies to mask the host MHCs (indirect pathway) and cyclosporin A (47). surviving dopamine cells 6 weeks after transplantation.
Limited survival of concordant (between closely related
Although the immune response to brain xenografts is blunted compared with peripheral xenografts and no species) xenografts in our study has parallels in the literature. Although the majority of neural xenografts are hyperacute rejection process occurs, recent studies (4,16) have underscored the importance of the antibody and rejected within 3 weeks of grafting (21,41), several investigators have found 36-42% survival of concordant complement-mediated immune response in neural xenograft rejection. We cannot exclude the possibility that mouse-to-rat neural xenografts at 5-6 weeks postgrafting (7, 22) . Surviving wild-type xenografts showed mas-such humoral immune responses play a role in rejection of MHC-deficient xenografts. Anti-C5 complement anti-sive infiltration of host MHC class II + and activated host microglia at 6 weeks postgrafting, demonstrating that bodies and expression of human CD59 (a cell surface complement inhibitor) might provide some protection to these grafts were subject to host immune recognition and ongoing rejection. Together these findings demon-brain xenografts (16). In discordant, porcine-to-rat xenografts, the most pronounced deposition of IgM and C3 strate that the time course for rejection of concordant neural xenografts is highly variable, for reasons that may (pivotal convertase for all known complement pathways: classical, alternative, and lectin) occurred between 10 include: 1) state of the host immune system, 2) potential effects of the 6-OHDA lesion on inflammatory and im-and 21 days after transplantation (4). Attempts to inhibit complement attack on the xenograft using complement mune mediators in the brain, and 3) variations in the transplantation procedure. The survival of MHC class depletion with cobra venom factor delayed complement deposition, but did not prevent graft rejection (4).
I-deficient grafts appeared inferior. This result is expected because cells lacking or displaying mismatched
In light of an ongoing clinical trials testing the safety of transplantation of porcine neural cells into hu-MHC class I molecules on their surface are likely to be recognized as foreign by natural killer cells and killed. mans, questions arise as to suitability of conventionally bred animals as sources of tissue for xenotransplanta-It is now recognized, that "missing self" recognition allows natural killer cells to identify as nonself and elim-tion and use of classical immunosuppression (15) . This tissue has variable genetic background and may be con-inate aberrant and foreign cells (51).
Despite removal of MHC molecules and consequent taminated with potentially dangerous viral DNA. Conventional breeding is also not well suited for genetic disabling of the direct (donor MHC-mediated) pathway for T-cell activation, some grafts were still rejected. This engineering of the cells used in transplantation. By contrast, animal cloning allows for screening of the tis-finding supports the view that neural xenograft rejection can proceed via an indirect (host MHC-mediated) anti-sues for viral DNA and enables the selection of virusfree cells as nuclear donors for the creation of clones. gen presentation pathway. Even in the absence of donor MHCs, other xenoantigens expressed on donor cells are Because fetal cells can be genetically modified they can serve as source of nuclei for the generation of capable of binding to host MHCs. Such xenoantigen/host MHC complexes activate host T cells and initiate the cloned transgenic animals. Sheep transgenic for clotting factor X (49) and cows transgenic for LacZ (10) rejection process. We have observed infiltration of host MHC class II + antigen-presenting cells in all types of have been successfully created. Gene targeting is now also possible in fibroblasts, xenografts including sham grafts consisting only of saline. Grafts of MHC class II-deficient tissue had signifi-and fibroblast nuclei are routinely used for cloning (42) .
We have previously shown that embryonic dopamine cantly fewer infiltrating host MHC class II + cells when compared with the wild-type grafts, but in some cases cells obtained from cloned transgenic cows are suitable for cell transplantation therapies (60). The ability to cre-MHC class II-deficient grafts were still rejected. These results demonstrate that the indirect pathway for antigen ate genetically modifiable cloned tissue opens the possibility for creating rejection-resistant tissues for xeno-presentation is active and important during the rejection process and that the removal of donor MHCs is suffi-transplantation. Future genetic modifications to MHCs and other immunoregulatory genes in cloned mamma-cient to delay, but not prevent, xenograft rejection. The importance of the indirect pathway in neural xenograft lian tissue might allow generation of tissues that resist rejection. The combination of genetic modification of rejection has been underscored by a recent report showing that rat ventral mesencephalic tissue transplanted the donor tissue and antibody-mediated modification of the immune system of the transplant recipient may fur-into brains of MHC class II-deficient mice survived significantly better than identical transplants into wild-type ther protect neural xenografts from chronic rejection. mouse recipients (17). Partial solid graft protection in a ACKNOWLEDGMENTS: We thank Elenora Kushnir for her model of hamster-to-rat cardiac xenograft has been plantation of transgenic fetal pig dopamine neurons to rats and systemic prevention of host complement-mediated
